Cargando…
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo
The efficacy of targeting the MAPK signaling pathway in patients with melanoma is limited by the rapid development of resistance mechanisms that result in disease relapse. In this article, we focus on targeting the DNA repair pathway as an antimelanoma therapy, especially in MAPK inhibitor resistant...
Autores principales: | Fröhlich, Lisa Marie, Niessner, Heike, Sauer, Birgit, Kämereit, Sofie, Chatziioannou, Eftychia, Riel, Simon, Sinnberg, Tobias, Schittek, Birgit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478790/ https://www.ncbi.nlm.nih.gov/pubmed/37674529 http://dx.doi.org/10.1158/2767-9764.CRC-23-0101 |
Ejemplares similares
-
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
por: Kosnopfel, Corinna, et al.
Publicado: (2017) -
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
por: Makino, Elena, et al.
Publicado: (2018) -
Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition
por: Makino, Elena, et al.
Publicado: (2020) -
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors
por: Folly-Kossi, Helena, et al.
Publicado: (2023) -
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)